Kornimate/medical-research-clean huggingface dataset:
restoration of walking in multiple sclerosis using treadmill training.

Conditions: Multiple Sclerosis

Summary: the primary purpose of this study is to collect preliminary and pilot data to begin to determine whether the use of body weight support treadmill therapy (bwstt) with and without driven-gait-orthotics (dgo), results in improved motor recovery and ambulation ms patients with gait impairment

gait impairment is a major cause of ongoing disability in patients with multiple sclerosis (ms). new treadmills that provide body weight support and even robotic assistance to the lower limbs have recently been developed and are now commercially available. these treadmills allow the subject to execute the integrated process of walking in a task-specific manner that is repetitively reinforced in a normal pattern. data from studies using these body-weight supported treadmills (bwstt) in spinal cord injury and stroke patients suggest that intensive task-specific gait rehabilitative training may help to restore a normative gait pattern, improve overground walking and enhance quality of life in multiple sclerosis patients with neurological gait impairment. in this study, we propose a series of prospective longitudinal clinical studies to collect pilot data on the use of task-specific bwstt +/- lokomat on improving ambulation, motor function and quality of life for ms patients with mild to moderate gait difficulty. pilot data will also be collected for the effect conventional rehabilitation has on ambulation and motor outcomes as well as how these outcomes change during usual care. our clinical research goals are to capture the initial pilot data (mean changes and variances in ambulation, motor, fatigue and quality of life outcomes) to facilitate the design of a larger clinical trial to test efficacy if these preliminary data are promising. the planned studies will study the effect of two forms of task specific training (bwstt alone and bwstt combined with lokomat) compared to conventional gait rehabilitative methods and usual care

Eligibility criteria:
inclusion criteria: * clinical diagnosis of ms by mcdonald criteria. edss level between 4-6.5. exclusion criteria: * cardiovascular: recent mi \ 190/110 mmhg, uncontrolled diabetes (blood glucose 2x above the upper limit of normal or non-fasting blood drain). * symptomatic fall in blood pressure (\>30mm hg), when upright in the body support apparatus, despite medical therapy. * circulatory problems, history of vascular claudication or pitting edema. * cognitive impairment mmse \< 21. * body weight over 150 kg (structural limits of the lokomat). * lower extremity injuries that limit range of motion or function. * joint problems (hip or leg) that limit range of motion or cause pain with movement despite treatment. * unstable fractures. * pressure sores with any skin breakdown in areas in contact with the body harness or dgo apparatus. * chronic and ongoing alcohol or drug abuse. * pre-morbid, ongoing depression or psychosis.

Keywords: disability gait multiple sclerosis rehabilitation robot
welcoming by design pilot: reducing structural stigma by changing clinic systems and architectural design

Conditions: Hiv

Summary: the purpose of this study is to test the feasibility and acceptability of implementing clinic system changes and physical structures in uganda to improve aesthetics, welcome, and privacy to reduce hiv stigma, improve retention-in-care, and improve the patient experience. to evaluate pilot/implementation outcomes, the outcomes of fidelity, feasibility, and acceptability will be assessed prior to intervention. after the changes are done to two hiv interventions clinics, the outcome surveys will assess if the changes were disruptive or impeded the workings of the clinics.


Eligibility criteria:
inclusion criteria: * adults 18 and older * enrolled in the hiv clinics where we are working * able to independently consent for interview, survey, or focus group. exclusion criteria: * unable to provide consent * does not speak english or luganda (local language around kampala and entebbe)
effects of glucagon like peptide-1 on haemodynamic parameters

Conditions: Heart Failure

Summary: glucagon-like peptide-1 (glp-1) is an incretin hormone that regulates plasma glucose, and glp-1 analogues were recently introduced for the treatment of acute myocardial infarction. the investigators planned to evaluate the effects of liraglutide on haemodynamic parameters in patients with heart failure.

heart failure (hf) is a major cause of morbidity and mortality world wide. glucagon-like peptide-1 (glp-1) is an incretin hormone that regulates plasma glucose, and has direct effects on the cardiovascular system. in our previous study, the glp-1 analogue liraglutide could improve left ventricular function in patients with non-st-segment elevation myocardial infarction. however, the effects of glp-1 on hf patients remain unclear. pulse indicator continuous cardiac output (picco) technology is a combination of transpulmonary thermodilution and pulse contour analysis, which measures hemodynamic variables (left ventricular ejection fraction, volumes, and mass) in a fast and feasible way. therefore, the aim of this study was to evaluate the effects of liraglutide on hemodynamic variables in hf patients using the picco system.

Eligibility criteria:
inclusion criteria: patients with hf were eligible for the study. diagnosis of hf was based on an impaired ejection fraction (\<50%). exclusion criteria: patients were also excluded for the following reasons: unconscious at presentation; valvular heart disease, cardiogenic shock, hypoglycaemia, or diabetic ketoacidosis; or renal insufficiency.
unifying advanced treatment with advanced imaging

Conditions: Gastrointestinal Stromal Tumor (GIST)

Summary: the study investigates response assessment of gastrointestinal stromal tumors using dual energy ct (dect) in patients undergoing targeted therapy with a tki inhibitor.

patients treated with targeted therapies by tyrosine kinase inhibition (tki) almost always show different response patterns than tumors treated with cytotoxic chemotherapy. tumor manifestations treated with targeted therapies often show only minor measurable changes in tumor size despite inhibition of tumor proliferation. decrease in tumor size fulfilling the criteria of a partial remission according to recist may occur at a delayed stage of treatment after several months (pmid 19620483). sometimes, even an initial increase of maximum tumor diameters may be observed although those patients are treatment responders with respect to 'hard' study endpoints like overall survival or progression free survival. as a result, patients often are misclassified too early as non-responders. as a consequence, successful treatment is not recognized or decisions towards a less effective second-line therapy are made. dual energy ct (dect) is a new and robust ct method that allows to exactly quantify the intra-tumoral amount of intravenously injected iodinated contrast material pmid 21822784). thus, the technique can be considered as a simple and reliable surrogate of tumor perfusion (pmid 21822784, 21934517, 20498609, 18677487). initial studies have demonstrated a high accuracy of dect in the differentiation of benign and malignant tumors in the kidney or lung (pmid 20498609, 18677487, 18796658). furthermore, it has been demonstrated that the amount of iodine in lung tumors correlates with tumor glucose metabolism (pmid 21822784). these findings confirm the results of previous studies that have demonstrated the relationship between tumor perfusion, tumor microvessel density and glucose metabolism (pmid 15304661). the hypothesis of the study is that dect is the more accurate diagnostic tool to evaluate immediate therapeutic response in patients with gist undergoing tki inhibitor therapy (in most cases glivec ®) than evaluating by recist, world health organization (who) and choi criteria.

Eligibility criteria:
inclusion criteria: * general inclusion criteria for tki treatment according to general medical standard procedures exclusion criteria: * general inclusion criteria for tki treatment according to general medical standard procedures

Keywords: gastrointestinal stromal tumor (gist) dual energy ct tyrosine kinase inhibitor (tki)
pathway ch s&e registry

Conditions: Cluster Headache

Summary: monitor the safety and performance of the pulsante microstimulator system.


Eligibility criteria:
inclusion criteria: 1. patient meets ce marked labeling for cluster headache. 2. patient has the ability to read, comprehend and reliably record information as required by the protocol. 3. patient is able to provide written informed consent prior to participation in the study. exclusion criteria: 1. patient has other significant pain problem that might confound the study assessments in the opinion of the investigator.
a comparative study of sibling oocytes: icsi vs. the imsi sperm selection method

Conditions: Infertility

Summary: the aim of this research is to compare sibling oocytes using two sperm selection methods for choosing the best quality spermatozoa before they are injected into oocytes and the influence of each of these methods on embryo quality and ivf outcome.


Eligibility criteria:
inclusion criteria: * males aged 18-60 * females aged 18-35 * males defined as moderate ota or isolated teratozoospermia with less than 4% morphologically normal spermatozoa * patients with 0.5- 7% normal sperm according to msome analysis * females with normal fsh and amh values * females who have retrieved at least 6 oocytes in previous cycles * couples who have had at least 2 failed ivf-icsi cycles exclusion criteria: * couples who have been exposed to heavy smoking, drugs and chronic diseases * males who have undergone testicular surgery (tese) or defined as severe ota * females with egg factor infertility
transcutaneous electrical nerve stimulation (tens) and fibromyalgia (fm)

Conditions: Fibromyalgia

Summary: fibromyalgia as a clinical syndrome is defined by chronic widespread muscular pain, fatigue and tenderness with hyperalgesia to pressure over tender points. pain associated with fibromyalgia can interfere with daily function, work, and social activities. thus, one of the main treatments for patients with fibromyalgia must focus on pain relief to allow the person to function more independently both at home and at work. although the etiology of fibromyalgia is unknown, there is clearly enhanced sensitization in the central nervous system pain pathways as demonstrating by decreases in pressure pain thresholds, reduced central inhibition, and enhanced temporal summation. reducing pain in people with fibromyalgia would help increase the patient's ability to return to work, perform activities of daily living and thus improve the quality of life for the patient. transcutaneous electrical nerve stimulation (tens) is a modality utilized in physical therapy that delivers electrical stimulation through the skin and is used for both acute and chronic pain. tens works by reducing central excitability and increasing central inhibition. thus, the investigators hypothesize that application of transcutaneous electrical nerve stimulation (tens) to patients with fibromyalgia (fm) will reduce pain, reduce central excitability by restoring diffuse noxious inhibitory controls (dnic), and reduce temporal summation and that this decrease in pain and/or central excitability will improve function. the primary aim of the study is to test the effectiveness of tens on pain and central excitability in a crossover design study for patients with fibromyalgia with random assignment to three treatments: no treatment control, placebo tens and active high frequency tens. a secondary aim is to test the effect of decreased pain and central excitability on function in patients with fibromyalgia.

the study will be a simple crossover design with the following three treatments (1) active tens, (2) placebo tens or (3) no treatment control randomly assigned. subjects will draw the order for treatments (a, b, and c) out of a bowl at the initial testing session. this will determine the order of the testing. each subject will receive all 3 treatments in random order. the following tools will be used to measure subject characteristics (fibromyalgia impact questionnaire, tampa scale of kinesiophobia), pain (mcgill pain questionnaire and visual analogue scale), central excitability (pressure pain thresholds, temporal summation and dnic) and function (6 minute walk test, range of motion, sit to stand test).

Eligibility criteria:
inclusion criteria: * fibromyalgia diagnosis by a physician * history of cervical or lumbar pain exclusion criteria: * tens use in the last 5 years * pacemaker * no use of opioids

Keywords: fibromyalgia transcutaneous electrical nerve stimulation (tens)
chocolate consumption in healthy pregnant women trial

Conditions: Hypertension Pregnancy-induced

Summary: the purpose of this study is to to test the feasibility of design methods and procedures for later use on a larger scale and to examine the acute and chronic effect of consumption of flavanol-rich chocolate on endothelium function and blood pressure in healthy pregnant women.


Eligibility criteria:
inclusion criteria: * non-smoking normotensive women aged from 18 to 35 years, between the 7 and 12 weeks of gestation (documented by ultrasound) and having a live fetus confirmed by fetal heart auscultation exclusion criteria: * patients with family history of premature cardiovascular disease * chronic hypertension * currently or previously use of medications interfering with glucose or lipids metabolism. * use of supplements or natural health products that interfere with blood pressure. * consumption of 1 or more alcohol drink per day. * allergy or intolerance to nuts or chocolate.

Keywords: cacao chocolate theobromine flavonoids pregnant women hypertension pregnancy-induced pre-eclampsia epicatechin
evaluation and treatment of heart disease in patients not participating in research

Conditions: Arrhythmia; Congenital Heart Defect; Heart Disease

Summary: there is an important need to maintain clinical skills, provide quality training and expertise, and provide an environment that stimulates ideas for clinical research. this study permits inpatient evaluation and management of patients with heart disease who do not qualify to participate in studies currently being conducted by the cardiology branch of the national heart, lung, and blood institute.

there is an important need to maintain clinical skills, to ensure adequate training and expertise, and provide an environment that stimulates ideas for clinical research. this protocol permits inpatient evaluation and management of patients with heart disease who do not fulfill criteria for participation in existing cardiology branch research protocols.

Eligibility criteria:
patients with signs or symptoms of heart disease. patients selected because of either medical or research interest to the principal investigator. patients must not have unstable angina pectoris, unstable course following recent (within one month) myocardial infarction. must not be in new york heart association functional class iv heart failure. a positive pregnancy test will obviate any cardiovascular testing requiring ionizing radiation.

Keywords: training protocol cardiac diagnosis congenital heart disease acquired heart disease arrhythmias
babe(body appreciation and better eating), add some self-compassion

Conditions: Body Image; Eating Behavior; Binge Eating; Nutrition, Healthy; Disordered Eating

Summary: body dissatisfaction is most common among girls in their teenage years and young adulthood, this is also around the time where the risk of developing binge eating disorder is the highest. black/african american girls are more likely to engage in binge eating behaviors compared to their white american counterparts; however, they receive less help for eating issues. further, increase rates of obesity in the black/african american population may indicate that binge eating may be a bigger problem for this population than discussed. therefore, the primary purpose of this randomized controlled pilot is to assess the feasibility of this pilot study to be used in a large scale fully-powered study. the secondary purpose of this study is to assess if two different nutrition and body image programs elicit positive outcomes among black/african american teenage girls who indicate a desire to improve body image.


Eligibility criteria:
inclusion criteria: * female * black (afro-latina)/african american teenage girls * age 13 to 18 years old * attend high school in the united states * interest in nutrition exclusion criteria: * eating disorder diagnosis * pregnancy
presbyopic supracor treatment for near myopic/hyperopic pseudophakic eyes

Conditions: Myopia; Hyperopia; Presbyopia

Summary: this clinical study has been planned to determine the effectiveness of a special laser treatment intended to correct both near and distance vision in patients who have undergone previous cataract surgery.

this clinical study has been planned to evaluate the safety and effectiveness of the supracor presbyopic excimer laser treatment algorithm for near myopic and near hyperopic indications, with or without astigmatism, when performed on the cornea of pseudophakic eyes implanted with a monofocal iol.

Eligibility criteria:
inclusion criteria: * subjects must be at least 45 years old * subjects must read, understand, and sign an informed consent form (icf). * subjects must be willing and able to return for scheduled follow-up examinations through 6 months after surgery. * subjects must have undergone previous uncomplicated cataract surgery with monofocal iol implant in the study eye at least 3 months prior to study enrollment. * subjects must have up to +/- 2.0 (d) of absolute spherical myopia or hyperopia (not spherical equivalent), with up to +/- 2.0 d of refractive astigmatism (not corneal astigmatism) by manifest subjective refraction. the spherical equivalent must be no more than +/- 2.0 d. * subjects who have be screened successfully for acceptance of the supracor simulation exclusion criteria: * subjects for whom the combination of their baseline corneal thickness and the planned operative parameters for the lasik procedure would result in less than 250 microns of remaining corneal thickness below the flap postoperatively. * subjects for whom the preoperative assessment of the ocular topography indicates that one or both eyes are not suitable candidates for treatment based upon the suggested computer-simulated treatment plan (e.g. keratoconus).

Keywords: myopia hyperopia presbyopia pseudophakia lasik
trial of activated marrow infiltrating lymphocytes alone or in conjunction with an allogeneic granulocyte macrophage colony-stimulating factor (gm-csf)-based myeloma cellular vaccine in the autologous transplant setting in multiple myeloma

Conditions: Multiple Myeloma

Summary: patient population: patients with active myeloma (stage ii/iii) that have completed induction therapy and are eligible for an autologous stem cell transplant. number of patients: will treat a total of 32 evaluable patients in a 1:1 randomization of amils vs amils plus vaccine. an evaluable patient is defined as one which has received the activated mils and is at least 6 months post-transplant. study objectives: disease response as determined by the blade' criteria will be the primary endpoint of the trial at one year. additional study endpoints include progression free survival, parameters of t cell reconstitution, anti-tumor immune responses as well as the effect on osteoclastogenesis and clonogenic myeloma precursor cells.


Eligibility criteria:
inclusion criteria: * durie-salmon stage ii or iii multiple myeloma * newly diagnosed either prior to receiving treatment or having completed induction therapy * relapsed myeloma not previously transplanted within the past 5 years * measurable serum and/or urine m-protein from prior to induction therapy documented and available. a positive serum free lite assay is acceptable * age greater than 18 years old * ecog performance status of 0 - 2 * meet all institutional requirements for autologous stem cell transplantation * the patient must be able to comprehend and have signed the informed consent exclusion criteria: * diagnosis of any of the following plasma cell disorders: poems syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein \[m-protein\] and skin changes) non-secretory myeloma (no measurable protein on serum free lite assay) * plasma cell leukemia * amyloidosis * use of corticosteroids (glucocorticoids) within 21 days of pre-transplant vaccine or bone marrow collection * use of any myeloma-specific therapy other than lenalidomide within 21 days of pre-transplant vaccine * in a complete remission at the time of bone marrow collection * infection requiring treatment with antibiotics, antifungal, or antiviral agents within seven days of vaccination or bone marrow collection * participation in any clinical trial, within four weeks prior to vaccination or bone marrow collection on this trial, which involved an investigational drug or device * history of malignancy other than multiple myeloma within five years of vaccination or bone marrow collection, except adequately treated basal or squamous cell skin cancer * active autoimmune disease (e.g., rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosis) requiring systemic treatment. hypothyroidism without evidence of grave's disease or hashimoto's thyroiditis is permitted * evidence of spinal cord compression at time of transplant

Keywords: multiple myeloma
open-label study to assess the safety/tolerability in patients with solid tumors

Conditions: Solid Tumors and Hematologic Malignancy

Summary: to establish the maximum tolerated dose (mtd) of incb007839 given as multiple doses for 28 days and to determine if a higher mtd can be established when incb007839 is administered in combination with prophylactic anticoagulation and with a 2 and a half day (5 doses) treatment interruption every two weeks.


Eligibility criteria:
inclusion criteria: * either non-small cell lung cancer, hormone-refractory prostate cancer, colorectal cancer, breast cancer, or squamous cell cancer of the head and neck that is refractory to standard treatment or for which no effective treatment exists. the patient must have a life expectancy of 12 weeks or longer. * eastern cooperative oncology group (ecog) performance status of 0 or 1 exclusion criteria: * received any anticancer medications in the 28 days prior to receiving their first dose of study medication * evidence of venous thrombosis by flow doppler examination at screening * a history of thrombosis or a coagulation disorder * patients with a contraindication to use of low dose warfarin and/or aspirin. * any unresolved toxicity greater than grade 2 from previous anticancer therapy, except for stable chronic toxicities not expected to resolve * brain metastases or spinal cord compression * impaired renal function * inadequate bone marrow reserve